Acne Inversa, Hidradenitis Suppurativa, Suppurative Hidradenitis
Conditions
Brief summary
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.
Interventions
DRUGbermekimab
bermekimab 2 mL (200 mg/mL) pre-filled syringe
DRUGplacebo
placebo 2 mL pre-filled syringe
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Patients will be randomized to every week bermekimab injections, every other week bermekimab injections, or every week placebo injections.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent provided by the participant * Male or female, age greater than or equal to (\>=) 18 years * Naïve to OR failure of prior targeted biologic therapy for Hidradenitis Suppurativa (HS) (including anti-TNF, anti-IL-17, or JAK inhibitor therapy) * Diagnosis of HS for at least 1 year prior to screening. * HS affecting at least two distinct anatomic areas, one of which is Hurley II or III stage. * A total body count of abscesses and inflammatory nodules (AN) of at least 3. * Full understanding of the procedures of the study protocol and willingness to comply with them. * In case of female participants of childbearing potential, willingness to use one method of contraception of high efficacy during the entire study period. This method can be hormonal contraceptives or one of the following: condoms, diaphragm, or an intrauterine device. Women of non-childbearing potential include those considered to have a medical history that indicates that pregnancy is not a reasonable risk, including post-menopausal women and those with a history of hysterectomy or surgically sterilized.
Exclusion criteria
* Age below 18 years. * History of treatment with bermekimab for any reason. * Receipt of oral antibiotic treatment for HS within 28 days prior to baseline. * Receipt of prescription topical therapies for the treatment of HS within 14 days prior to baseline, and/or systemic non-biologic therapies for HS (immunosuppressants, corticosteroids, retinoids, or hormonal therapies) within 28 days prior to screening. * Participant has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to baseline. * History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies. * Has received a live (attenuated) vaccine over the 28 days prior to screening. * Participant received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to baseline. * If entering the study on concomitant oral analgesics (including opioids) for non-HS-related pain: (a) Participant on opioid analgesics within 14 days prior to baseline visit; (b) Participant not on a stable dose of non-opioid oral analgesics for at least 14 days prior to baseline visit (PRN is not considered a stable dose). * Participant requires or is expected to require opioid analgesics for any reason (excluding tramadol). * Participant has a draining fistula count of greater than 20 at baseline. * Major surgery (requiring general anesthesia or respiratory assistance) within 28 days prior to Day 0 of start of study drug. * Hepatic dysfunction defined as any value of transaminases, of γ-glutamyl transpeptidase (γGT) or of total bilirubin \> 3x upper normal limit. * Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis \[TB\], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution. * Stage C Child-Pugh liver cirrhosis. * History of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). * Neutropenia defined as \<1,000 neutrophils/mm3. * Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Week 12 | HiSCR was defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Baseline, Week 12, Week 16 | Change form baseline in total AN count at Weeks 12 and 16 was reported. Abscess and inflammatory nodule were counted for the hidradenitis suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions. |
| Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Baseline, Week 12, Week 16 | Change form baseline in number of draining fistulas at Weeks 12 and 16 was reported. Draining fistula were defined as fistulas that drain serious or purulent fluid, either spontaneously or by gentle palpation. |
| Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | Week 16 | HiSCR was defined as at least 50% reduction in AN count with no increase in abscess count and no increase in draining fistula count relative to baseline. |
| Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Baseline, Week 12, Week 16 | Change from baseline in mHSS at Weeks 12 and 16 was reported. The sartorius scale was used to quantify the severity of HS. Points were awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between 2 lesions (2-6 points, 0 if no lesions); and if lesions were separated by normal skin (yes: 0 points; no: 6 points). The total sartorius score was the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS. |
| Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Weeks 12 and 16 | HS-PGA was physician assessment of severity of disease based on 6-point scale:Clear (0)=total number of abscesses, inflammatory nodule, non-inflammatory nodule and draining fistulas was 0;Minimal (1)=total number of abscesses,draining fistulas, inflammatory nodule was 0, presence of non-inflammatory nodule;Mild (2)=total number of abscesses, draining fistulas was 0, total number of inflammatory nodule was 1-4, or presence of 1 abscess or draining fistula and absence of any inflammatory nodules;Moderate (3)=total number of abscesses and draining fistulas was 0, total number of inflammatory nodule was at least 5; or presence of 1 abscess or draining fistula and at least 1 inflammatory nodule; or 2-5 abscesses or draining fistulas, fewer than 10 inflammatory nodule;Severe (4)=total number of abscesses or draining fistulas was 2-5, total number of inflammatory nodule was at least 10;Very severe (5)=more than 5 abscesses or draining fistulas.Higher score indicated more severity of disease. |
| Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The HADS was an instrument for screening anxiety and depression in non-psychiatric populations; repeated administration also provides information about changes in a participant's emotional state. It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14. Each item receives a score from 0 to 3 on a Likert Scale. The total score for each HADS-A and HADS-D scale was obtained by adding the individual scores for each item, with the maximum score 21. The presence or absence of depression and anxiety was defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 equal to (=) no anxiety; greater than (\>) 9 = anxiety; HADS (depression): 0-8 = no depression; \>9 = depression. |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | DLQI was a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The DLQI domains include symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The participant respond on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). The DLQI total score was derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (that is, negative change score) indicated improvement in the Quality of Life. |
| Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Baseline, Week 12, Week 16 | Change from baseline in NRS for pain and itch at Weeks 12 and 16 was reported. Participants were given a take-home diary to complete each night before bed. Participants were asked to report average pain, and worst moment pain as well as average itch and worst moment itch on a 0 to 10 NRS, where 0=no itch or no pain and 10=worst itch or worst pain. Higher score indicated more severity. |
| Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Week 12, Week 16 | The PGI-c was a single-item patient reported outcome (PRO) that assessed change in severity of skin pain due to HS. Participants rated how his/her HS had changed since the beginning of the study using a 7-point scale ranging from 1 to 7 where 1 indicates very much better, 2 indicates Much better', 3 indicates A little better, 4 indicates No change, 5 indicates A little worse, 6 indicates Much worse and 7 indicates Very much worse. |
| Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Week 12, Week 16 | The PGI-s was a single-item PRO that assessed change in a participant's impression of their disease severity. The PGI-s item asks the respondent to best describe how his/her HS symptoms are now (that is, check the one number that best describes how your HS symptoms are now) on a 4-point scale scored as: normal (1), mild (2), moderate (3), or severe (4). |
| Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Baseline, Week 12, Week 16 | HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours with a score range from 0 (no symptom experience) to 10 (worst possible symptom experience). A total symptom score also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period. Change from baseline in HS-related pain symptom score in the past 24 hours based on HSSD was reported. |
| Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The HSSD was a 7-item patient self-reported questionnaire that assessed 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms had a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. Each individual symptom scale score, ranging from 0-10, was summarized. A total symptom score, which also ranged from 0-10, was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period. |
| Serum Concentration of Bermekimab | Baseline (Week 0), Weeks 1, 2, 3, 4, 5, 8, 12, and 16 | Serum concentration of bermekimab was reported. This outcome measure was planned to be analyzed for specified arms only. |
| Reduction From Baseline in Serum Interleukin-6 (IL-6) | Baseline, Weeks 8, 12 and 16 | Reduction from baseline in serum IL-6 was reported. |
| Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The EQ-5D-3L was a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo (Week 0-16) Participants received placebo as subcutaneous (SC) injection at Weeks 0 and 1, and once every week (qw) from Week 2 through Week 16. | 52 |
| Bermekimab 400 mg q2w (Week 0-16) Participants received loading dose of bermekimab 800 milligrams (mg) (2\*400 mg) as SC injection at Weeks 0 and 1, followed by bermekimab 400 mg once every 2 weeks (q2w) alternating with matching placebo q2w through Week 16. | 50 |
| Bermekimab 400 mg qw (Week 0-16) Participants received loading dose of bermekimab 800 mg (2\*400 mg) as SC injection at Weeks 0 and 1, followed by bermekimab 400 mg qw through Week 16. | 51 |
| Total | 153 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Active Treatment+Safety F-U (Week 17-36) | Adverse Event | 0 | 0 | 0 | 1 | 0 | 0 |
| Active Treatment+Safety F-U (Week 17-36) | Death | 0 | 0 | 0 | 0 | 1 | 0 |
| Active Treatment+Safety F-U (Week 17-36) | Lost to Follow-up | 0 | 0 | 0 | 1 | 2 | 3 |
| Active Treatment+Safety F-U (Week 17-36) | Other | 0 | 0 | 0 | 0 | 3 | 1 |
| Active Treatment+Safety F-U (Week 17-36) | Withdrawal by Subject | 0 | 0 | 0 | 4 | 2 | 1 |
| Placebo Controlled Period (Weeks 0-16) | Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 |
| Placebo Controlled Period (Weeks 0-16) | Imprisonment/compulsory detention | 0 | 0 | 1 | 0 | 0 | 0 |
| Placebo Controlled Period (Weeks 0-16) | Other | 1 | 2 | 1 | 0 | 0 | 0 |
| Placebo Controlled Period (Weeks 0-16) | Withdrawal by Subject | 3 | 5 | 4 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo (Week 0-16) | Total | Bermekimab 400 mg qw (Week 0-16) | Bermekimab 400 mg q2w (Week 0-16) |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 10 Participants | 3 Participants | 5 Participants |
| Age, Categorical Between 18 and 65 years | 50 Participants | 143 Participants | 48 Participants | 45 Participants |
| Age, Continuous | 39 years STANDARD_DEVIATION 13.65 | 38.9 years STANDARD_DEVIATION 13.81 | 40.4 years STANDARD_DEVIATION 14.02 | 37.2 years STANDARD_DEVIATION 13.85 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 3 Participants | 2 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black or African American | 14 Participants | 43 Participants | 13 Participants | 16 Participants |
| Race/Ethnicity, Customized More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 3 Participants | 7 Participants | 3 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 33 Participants | 99 Participants | 33 Participants | 33 Participants |
| Region of Enrollment UNITED STATES | 52 Participants | 153 Participants | 51 Participants | 50 Participants |
| Sex: Female, Male Female | 35 Participants | 113 Participants | 37 Participants | 41 Participants |
| Sex: Female, Male Male | 17 Participants | 40 Participants | 14 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 52 | 0 / 50 | 0 / 51 | 0 / 48 | 1 / 43 | 0 / 43 |
| other Total, other adverse events | 16 / 52 | 14 / 50 | 13 / 51 | 10 / 48 | 4 / 43 | 6 / 43 |
| serious Total, serious adverse events | 2 / 52 | 0 / 50 | 1 / 51 | 0 / 48 | 3 / 43 | 2 / 43 |
Outcome results
Primary
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
HiSCR was defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
Time frame: Week 12
Population: The full analysis set (FAS) included all randomized participants who received at least 1 dose of study agent.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 46.2 Percentage of participants |
| Bermekimab 400 mg q2w (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 44.0 Percentage of participants |
| Bermekimab 400 mg qw (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 54.9 Percentage of participants |
Secondary
Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16
Change form baseline in total AN count at Weeks 12 and 16 was reported. Abscess and inflammatory nodule were counted for the hidradenitis suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 12 | -3.7 Abscess and inflammatory nodule | Standard Deviation 7.95 |
| Placebo (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 16 | -5.1 Abscess and inflammatory nodule | Standard Deviation 8.11 |
| Bermekimab 400 mg q2w (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 12 | -4.0 Abscess and inflammatory nodule | Standard Deviation 6.97 |
| Bermekimab 400 mg q2w (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 16 | -4.8 Abscess and inflammatory nodule | Standard Deviation 8.31 |
| Bermekimab 400 mg qw (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 12 | -5.2 Abscess and inflammatory nodule | Standard Deviation 6.18 |
| Bermekimab 400 mg qw (Week 0-16) | Change Form Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Weeks 12 and 16 | Week 16 | -5.1 Abscess and inflammatory nodule | Standard Deviation 6.54 |
Secondary
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16
DLQI was a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The DLQI domains include symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The participant respond on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). The DLQI total score was derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (that is, negative change score) indicated improvement in the Quality of Life.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 12 | -3.8 scores on a scale | Standard Deviation 4.91 |
| Placebo (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 16 | -4.2 scores on a scale | Standard Deviation 5.92 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 12 | -4.5 scores on a scale | Standard Deviation 7.09 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 16 | -5.1 scores on a scale | Standard Deviation 7.09 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 12 | -4.6 scores on a scale | Standard Deviation 5.07 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 16 | Week 16 | -4.7 scores on a scale | Standard Deviation 5.27 |
Secondary
Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16
The EQ-5D-3L was a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 12 | 7.2 scores on a scale | Standard Deviation 14.3 |
| Placebo (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 16 | 9.3 scores on a scale | Standard Deviation 14.23 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 12 | 6.9 scores on a scale | Standard Deviation 14.69 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 16 | 7.7 scores on a scale | Standard Deviation 14.6 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 12 | 3.7 scores on a scale | Standard Deviation 19.2 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Health Status as Assessed by EuroQol-5 Dimension Instrument-3 Levels (EQ-5D-3L) Visual Analogue Scale (VAS) Scores at Weeks 12 and 16 | Week 16 | 6.1 scores on a scale | Standard Deviation 17.47 |
Secondary
Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours with a score range from 0 (no symptom experience) to 10 (worst possible symptom experience). A total symptom score also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period. Change from baseline in HS-related pain symptom score in the past 24 hours based on HSSD was reported.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 12 | -1.7 scores on a scale | Standard Deviation 2.81 |
| Placebo (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 16 | -1.9 scores on a scale | Standard Deviation 2.83 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 12 | -1.8 scores on a scale | Standard Deviation 3.05 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 16 | -1.9 scores on a scale | Standard Deviation 2.97 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 12 | -1.9 scores on a scale | Standard Deviation 2.81 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Weeks 12 and 16 | Week 16 | -1.9 scores on a scale | Standard Deviation 2.85 |
Secondary
Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16
The HSSD was a 7-item patient self-reported questionnaire that assessed 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms had a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. Each individual symptom scale score, ranging from 0-10, was summarized. A total symptom score, which also ranged from 0-10, was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 12 | -1.9 scores on a scale | Standard Deviation 2.16 |
| Placebo (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 16 | -1.8 scores on a scale | Standard Deviation 2.01 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 12 | -2.1 scores on a scale | Standard Deviation 2.38 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 16 | -2.0 scores on a scale | Standard Deviation 2.33 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 12 | -2.1 scores on a scale | Standard Deviation 2.19 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hidradenitis Suppurativa Symptom Diary (HSSD) Total Symptom Score at Weeks 12 and 16 | Week 16 | -1.9 scores on a scale | Standard Deviation 2.29 |
Secondary
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16
The HADS was an instrument for screening anxiety and depression in non-psychiatric populations; repeated administration also provides information about changes in a participant's emotional state. It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14. Each item receives a score from 0 to 3 on a Likert Scale. The total score for each HADS-A and HADS-D scale was obtained by adding the individual scores for each item, with the maximum score 21. The presence or absence of depression and anxiety was defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 equal to (=) no anxiety; greater than (\>) 9 = anxiety; HADS (depression): 0-8 = no depression; \>9 = depression.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 12 | -1.7 scores on a scale | Standard Deviation 2.7 |
| Placebo (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 16 | -1.6 scores on a scale | Standard Deviation 3.19 |
| Placebo (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 12 | -0.6 scores on a scale | Standard Deviation 2.58 |
| Placebo (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 16 | -0.5 scores on a scale | Standard Deviation 2.43 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 16 | -0.9 scores on a scale | Standard Deviation 2.53 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 12 | -1.4 scores on a scale | Standard Deviation 3.54 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 12 | -0.8 scores on a scale | Standard Deviation 2.41 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 16 | -1.8 scores on a scale | Standard Deviation 3.17 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 16 | -1.3 scores on a scale | Standard Deviation 3.15 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 16 | -1.8 scores on a scale | Standard Deviation 3.13 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS depression: Week 12 | -1.5 scores on a scale | Standard Deviation 3.48 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12 and 16 | HADS anxiety: Week 12 | -1.5 scores on a scale | Standard Deviation 3.65 |
Secondary
Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16
Change from baseline in mHSS at Weeks 12 and 16 was reported. The sartorius scale was used to quantify the severity of HS. Points were awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between 2 lesions (2-6 points, 0 if no lesions); and if lesions were separated by normal skin (yes: 0 points; no: 6 points). The total sartorius score was the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 12 | -24.0 scores on a scale | Standard Deviation 35.36 |
| Placebo (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 16 | -26.8 scores on a scale | Standard Deviation 43.19 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 12 | -13.2 scores on a scale | Standard Deviation 42.54 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 16 | -22.4 scores on a scale | Standard Deviation 44.53 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 12 | -26.1 scores on a scale | Standard Deviation 20.94 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Modified Hidradenitis Suppurativa Score (mHSS) at Weeks 12 and 16 | Week 16 | -24.1 scores on a scale | Standard Deviation 30.47 |
Secondary
Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16
Change form baseline in number of draining fistulas at Weeks 12 and 16 was reported. Draining fistula were defined as fistulas that drain serious or purulent fluid, either spontaneously or by gentle palpation.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 12 | -0.6 fistulas | Standard Deviation 1.9 |
| Placebo (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 16 | -0.6 fistulas | Standard Deviation 2.56 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 12 | 0.1 fistulas | Standard Deviation 4.54 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 16 | -0.5 fistulas | Standard Deviation 1.17 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 12 | -0.3 fistulas | Standard Deviation 0.82 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Number of Draining Fistulas at Weeks 12 and 16 | Week 16 | -0.3 fistulas | Standard Deviation 1.76 |
Secondary
Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16
Change from baseline in NRS for pain and itch at Weeks 12 and 16 was reported. Participants were given a take-home diary to complete each night before bed. Participants were asked to report average pain, and worst moment pain as well as average itch and worst moment itch on a 0 to 10 NRS, where 0=no itch or no pain and 10=worst itch or worst pain. Higher score indicated more severity.
Time frame: Baseline, Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 12 | -1.47 scores on a scale | Standard Deviation 1.987 |
| Placebo (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 16 | -1.52 scores on a scale | Standard Deviation 2.086 |
| Placebo (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 12 | -1.79 scores on a scale | Standard Deviation 2.356 |
| Placebo (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 16 | -1.66 scores on a scale | Standard Deviation 3.081 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 16 | -1.29 scores on a scale | Standard Deviation 2.94 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 12 | -1.92 scores on a scale | Standard Deviation 2.528 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 12 | -1.82 scores on a scale | Standard Deviation 2.767 |
| Bermekimab 400 mg q2w (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 16 | -1.80 scores on a scale | Standard Deviation 2.537 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 16 | -1.45 scores on a scale | Standard Deviation 2.66 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 16 | -1.63 scores on a scale | Standard Deviation 2.307 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Itch: Week 12 | -1.62 scores on a scale | Standard Deviation 2.764 |
| Bermekimab 400 mg qw (Week 0-16) | Change From Baseline in Numeric Rating Scale (NRS) for Pain & Itch at Weeks 12 and 16 | Pain: Week 12 | -1.67 scores on a scale | Standard Deviation 2.472 |
Secondary
Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16
The PGI-c was a single-item patient reported outcome (PRO) that assessed change in severity of skin pain due to HS. Participants rated how his/her HS had changed since the beginning of the study using a 7-point scale ranging from 1 to 7 where 1 indicates very much better, 2 indicates Much better', 3 indicates A little better, 4 indicates No change, 5 indicates A little worse, 6 indicates Much worse and 7 indicates Very much worse.
Time frame: Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 16 | 13 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 12 | 5 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 12 | 5 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 16 | 7 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 12 | 1 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 12 | 6 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 16 | 9 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 16 | 4 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 16 | 12 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 12 | 14 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 16 | 1 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 12 | 3 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 12 | 13 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 16 | 2 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 16 | 17 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 12 | 1 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 12 | 3 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 12 | 14 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 12 | 14 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 12 | 6 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 12 | 3 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 12 | 0 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 16 | 1 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 16 | 6 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 16 | 8 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 16 | 6 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 16 | 4 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 16 | 0 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 16 | 2 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 16 | 12 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 12 | 8 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 12 | 15 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | No change: Week 16 | 12 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little better: Week 12 | 6 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 12 | 7 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | A little worse: Week 16 | 7 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 12 | 5 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much better: Week 16 | 6 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 12 | 1 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Very much worse: Week 16 | 1 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much better: Week 16 | 3 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Change (PGI-c) at Week 12 and 16 | Much worse: Week 12 | 2 Participants |
Secondary
Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16
The PGI-s was a single-item PRO that assessed change in a participant's impression of their disease severity. The PGI-s item asks the respondent to best describe how his/her HS symptoms are now (that is, check the one number that best describes how your HS symptoms are now) on a 4-point scale scored as: normal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 12, Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 12 | 7 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 12 | 12 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 12 | 15 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 12 | 12 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 16 | 7 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 16 | 18 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 16 | 13 Participants |
| Placebo (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 16 | 10 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 12 | 19 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 16 | 15 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 12 | 0 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 16 | 3 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 16 | 22 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 12 | 3 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 12 | 19 Participants |
| Bermekimab 400 mg q2w (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 16 | 2 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 12 | 14 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 12 | 19 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 12 | 7 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 12 | 4 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Moderate: Week 16 | 11 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Mild: Week 16 | 16 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Normal: Week 16 | 8 Participants |
| Bermekimab 400 mg qw (Week 0-16) | Number of Participants With Patient Global Impression of Severity (PGI-s) at Weeks 12 and 16 | Severe: Week 16 | 8 Participants |
Secondary
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
HiSCR was defined as at least 50% reduction in AN count with no increase in abscess count and no increase in draining fistula count relative to baseline.
Time frame: Week 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 44.2 percentage of participants |
| Bermekimab 400 mg q2w (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 52.0 percentage of participants |
| Bermekimab 400 mg qw (Week 0-16) | Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 56.9 percentage of participants |
Secondary
Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16
HS-PGA was physician assessment of severity of disease based on 6-point scale:Clear (0)=total number of abscesses, inflammatory nodule, non-inflammatory nodule and draining fistulas was 0;Minimal (1)=total number of abscesses,draining fistulas, inflammatory nodule was 0, presence of non-inflammatory nodule;Mild (2)=total number of abscesses, draining fistulas was 0, total number of inflammatory nodule was 1-4, or presence of 1 abscess or draining fistula and absence of any inflammatory nodules;Moderate (3)=total number of abscesses and draining fistulas was 0, total number of inflammatory nodule was at least 5; or presence of 1 abscess or draining fistula and at least 1 inflammatory nodule; or 2-5 abscesses or draining fistulas, fewer than 10 inflammatory nodule;Severe (4)=total number of abscesses or draining fistulas was 2-5, total number of inflammatory nodule was at least 10;Very severe (5)=more than 5 abscesses or draining fistulas.Higher score indicated more severity of disease.
Time frame: Weeks 12 and 16
Population: The FAS included all randomized participants who received at least 1 dose of study agent.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 12 | 11.5 percentage of participants |
| Placebo (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 16 | 11.5 percentage of participants |
| Bermekimab 400 mg q2w (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 12 | 2.0 percentage of participants |
| Bermekimab 400 mg q2w (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 16 | 2.0 percentage of participants |
| Bermekimab 400 mg qw (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 12 | 17.6 percentage of participants |
| Bermekimab 400 mg qw (Week 0-16) | Percentage of Participants Who Achieved HS-PGA of Clear (0) or Minimal (1) or HS-PGA Score of Mild or Better (<=2) With at Least a 2-grade Improvement Relative to Baseline at Weeks 12 and 16 | Week 16 | 19.6 percentage of participants |
Secondary
Reduction From Baseline in Serum Interleukin-6 (IL-6)
Reduction from baseline in serum IL-6 was reported.
Time frame: Baseline, Weeks 8, 12 and 16
Population: Due to change in planned analysis, data was not collected for this outcome measure hence analysis was not performed.
Secondary
Serum Concentration of Bermekimab
Serum concentration of bermekimab was reported. This outcome measure was planned to be analyzed for specified arms only.
Time frame: Baseline (Week 0), Weeks 1, 2, 3, 4, 5, 8, 12, and 16
Population: The pharmacokinetic (PK) analysis set included all participants who received at least 1 complete dose of bermekimab and had at least 1 valid blood sample drawn for PK analysis after their first dose of bermekimab. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies participants who were evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 1 | 31.60 micrograms per milliliter (mcg/mL) | Standard Deviation 18.697 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 5 | 9.94 micrograms per milliliter (mcg/mL) | Standard Deviation 9.794 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 3 | 16.44 micrograms per milliliter (mcg/mL) | Standard Deviation 12.725 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 8 | 21.43 micrograms per milliliter (mcg/mL) | Standard Deviation 15.529 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 2 | 37.75 micrograms per milliliter (mcg/mL) | Standard Deviation 20.62 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 12 | 20.87 micrograms per milliliter (mcg/mL) | Standard Deviation 13.407 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 4 | 20.22 micrograms per milliliter (mcg/mL) | Standard Deviation 14.118 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 16 | 21.35 micrograms per milliliter (mcg/mL) | Standard Deviation 17.958 |
| Placebo (Week 0-16) | Serum Concentration of Bermekimab | Week 0 | 0.00 micrograms per milliliter (mcg/mL) | Standard Deviation 0 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 16 | 31.03 micrograms per milliliter (mcg/mL) | Standard Deviation 18.503 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 0 | 0.00 micrograms per milliliter (mcg/mL) | Standard Deviation 0 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 1 | 35.76 micrograms per milliliter (mcg/mL) | Standard Deviation 19.153 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 2 | 48.81 micrograms per milliliter (mcg/mL) | Standard Deviation 25.938 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 3 | 38.09 micrograms per milliliter (mcg/mL) | Standard Deviation 25.627 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 4 | 34.71 micrograms per milliliter (mcg/mL) | Standard Deviation 21.042 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 5 | 30.95 micrograms per milliliter (mcg/mL) | Standard Deviation 20.248 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 8 | 28.34 micrograms per milliliter (mcg/mL) | Standard Deviation 17.659 |
| Bermekimab 400 mg q2w (Week 0-16) | Serum Concentration of Bermekimab | Week 12 | 29.36 micrograms per milliliter (mcg/mL) | Standard Deviation 16.891 |